Ark Therapeutics is using its expertise and spare capacity to move into the contract manufacturing sector and is hoping to sign deals to produce the DNA-based medicine.
Innovator companies are increasingly offering contract services or manufacturing to provide an additional source of revenue, make potentially important contacts in the industry and help develop in-house knowledge and expertise.
The Florida Biologix team is committed to quality which ensures that your end product is optimal and the process exceeds expectations. Our collaborative approach ensures that the client is a partner and well informed throughout the project. Our team is flexible and experienced which ensures that technical or business issues are handled smoothly if they arise.
Our primary focus is to produce, test and/or fill cGMP compliant biopharmaceutical clinical trial material on time and at a reasonable price.
Some quick facts:
Oxford, UK – 1 June 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces updated results from open-label Phase I/II and II trials of TroVax in metastatic colorectal cancer and metastatic renal cancer. TroVax is Oxford BioMedica’s therapeutic cancer vaccine that targets the 5T4 tumour antigen. Two cross-trial analyses were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. In all trials, TroVax was well tolerated with no serious adverse events attributed to vaccination.
Roberts Biosolutions Ltd
Hillcoat Place, Edinburgh
United Kingdom
Email: info@genetherapyreview.com
Twitter: @gentherev
